Failure test of experimental Covid-19 immunoglobulin therapies
Four experimental Covid-19 treatments derived from the blood of recovered patients have failed tests, the drugmakers said.
Therapies from Emerging BioSolutions Inc., Grifols SA, and a consortium of companies that included Takeda Pharmaceutical Co. and CSL Behring have not helped inpatients in a government-funded pivotal studythe drugmakers said on Friday.
These failures mark a setback for the development of a class of Covid-19 treatments known as hyper-immune intravenous globulin therapies.
Doctors and researchers hoped the class could make valuable new additions to the limited arsenal of Covid-19 therapies, as the class had performed well against severe viral respiratory infections.
The companies have announced the failure of their experimental therapies in statements, although they declined to provide more details on the results.